Correlation of colony-forming cells, long-term culture initiating cells and CD34+ cells in apheresis products from patients mobilized for peripheral blood progenitors with different regimens

• Published in: Bone marrow transplantation (Basingstoke) Vol. 13; no. 4; pp. 479 - 485
• Main Authors: BENDER, J. G, LUM, L, WILLIAMS, S. F, UNVERZAGT, K. L, LEE, W, VAN EPPS, D, GEORGE, S, COON, J, GHALIE, R, MCLEOD, B, KAIZER, H
• Format: Journal Article
• Language: English
• Published: Basingstoke Nature Publishing Group 01.04.1994
• Subjects: Adult; Antigens, CD - analysis; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Blood Component Transfusion; Blood Transfusion, Autologous; Blood. Blood coagulation. Reticuloendothelial system; Breast Neoplasms - blood; Breast Neoplasms - drug therapy; Colony-Forming Units Assay; Cyclophosphamide - administration & dosage; Cyclophosphamide - pharmacology; Cyclophosphamide - therapeutic use; Etoposide - administration & dosage; Etoposide - pharmacology; Female; Flow Cytometry; Granulocyte Colony-Stimulating Factor - pharmacology; Granulocyte Colony-Stimulating Factor - therapeutic use; Hematopoiesis - drug effects; Hematopoietic Stem Cells - cytology; Humans; Immunologic Factors - pharmacology; Immunologic Factors - therapeutic use; Leukapheresis; Lymphoma, Non-Hodgkin - blood; Lymphoma, Non-Hodgkin - drug therapy; Medical sciences; Middle Aged; Neutropenia - chemically induced; Neutropenia - therapy; Ovarian Neoplasms - blood; Ovarian Neoplasms - drug therapy; Pharmacology. Drug treatments; Antineoplastic agent; Human; Chemotherapy; Granulocyte colony stimulating factor; Treatment; Hematopoiesis; Stem cell; Immunotherapy; Hematopoietic cell; Exploration; Blood; Colony forming cell
• ISSN: 0268-3369; 1476-5365

Peripheral blood progenitor cell (PBPC) populations used for transplantation were analyzed for the presence of CD34+ cells, colony-forming cells (initial CFC), and long-term culture initiating cells (LTC-IC) cultured on irradiated stroma for 5 weeks. Thirty-eight leukapheresis products were studied from 11 patients with breast cancer, 2 with non-Hodgkin's lymphoma and 1 with ovarian cancer harvested during recovery from either cyclophosphamide (CY) chemotherapy or cyclophosphamide-VP16 with G-CSF (CY-VP-G). CY-VP-G products had a threefold higher median number of mononuclear cells collected, a fivefold higher median concentration of CD34 and LTC-IC and a threefold higher concentration of initial-CFC when compared with CY products. CY-VP-G products had a significantly higher ratio of CFU-GM to BFU-E than the CY-mobilized products. Significant correlations of r = 0.89 and r = 0.68 were observed when comparing CD34 and CFC in products from CY or CY-VP-G patients, respectively. Analysis of the regression lines indicated that slopes of these regression lines were significantly different with a ratio of CD34 to initial CFC of 15:1 in the CY-VP-G products versus 5.2:1 with the CY products. These data indicate a higher cloning efficiency of the CD34+ population in the products from CY-mobilized patients. Significant correlations of r = 0.9 (CY) and r = 0.53 (CY-VP-G) were observed when the initial CD34 concentration and the LTC-IC were compared. Comparison of initial CFC with LTC-IC also showed significant correlations (r = 0.94, CY; r = 0.58, CY-VP-G) in samples from both patient groups.